Physician profile
Lance J Wright
NPI 1699756346
$18,612.59
in general payments reported to CMS, 2019-2025
55 companies · $5,719 in 2025
The $5,719 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,569 · 2020: $876 · 2021: $749 · 2022: $1,763 · 2023: $2,131 · 2024: $3,805 · 2025: $5,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $715 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,735.43 |
| Travel and Lodging | $714.64 |
| Education | $204.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,887.94 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Medtronic, INC. | $2,261.47 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Emd Serono, INC. | $1,348.96 | 2019-2025 | Mavenclad |
| Ucb, INC. | $967.12 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $898.74 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $752.85 | 2019-2025 | |
| Sk Life Science, INC. | $730.60 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $730.27 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Biogen, INC. | $619.27 | 2019-2025 | Vumerity, Tysabri |
| Lundbeck LLC | $613.32 | 2019-2025 | Vyepti |
| Genentech USA, INC. | $576.18 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Amgen INC. | $497.31 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $481.84 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $440.28 | 2019-2025 | |
| Argenx US, INC. | $402.63 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.